Exploring Demo Mode — data is read-onlySign Up Free
Back to protocol

Systematic Review: Screening

Identification

54 included / 1 excluded

Screening

43 included / 1 excluded

Eligibility

33 included / 0 excluded

Included

22 included / 0 excluded

Efficacy and Safety of RSVPreF Vaccine in Older Adults: Phase 3 RENOIR Trial Results

Walsh EE, Perez Marc G, Zareba AM, et al. — New England Journal of Medicine (2023)

IncludedIncluded

Real-World Effectiveness of RSV Vaccination Among Medicare Beneficiaries, 2023-2024

Surie D, Bonnell L, Adams K, et al. — MMWR Morbidity and Mortality Weekly Report (2024)

IncludedIncluded

ACIP Recommendations for RSV Vaccination in Adults Aged 60 Years and Older

Melgar M, Britton A, Roper LE, et al. — CDC Advisory Committee on Immunization Practices (2024)

EligibilityIncluded

Burden of RSV-Associated Hospitalizations Among US Adults, 2019-2023

Havers FP, Whitaker M, Melgar M, et al. — Clinical Infectious Diseases (2024)

ScreeningExcluded

Reason: Epidemiology only — no vaccine effectiveness data

Study team discussion: Data source selection and feasibility notes

Study team — Internal (2025)

IdentificationExcluded

Reason: Internal notes — not primary literature

Want to make screening decisions?

Sign up for free to unlock all features.

Sign Up Free
VaxEvidence | Real-World Evidence Platform for Vaccine Research